港股异动 | 白云山涨逾3% 拟筹备子公司广州医药赴港上市
格隆汇9月11日丨白云山(0874.HK)现报29.9港元,涨3.28%,暂成交299万港元,最新总市值486亿港元。白云山昨晚发布公告称,根据公司总体战略布局,结合广州医药有限公司业务发展需要,为进一步拓宽公司境外融资渠道,加速公司国际化战略的实施,公司董事会授权公司管理层启动分拆医药公司到港交所上市的前期筹备工作,医药公司董事会亦同意启动上市筹备工作。此外据悉,白云山上半年营收333.4亿元,同比增124.67%;上半年股东应占净利润25.48亿元,同比下降2.71%。营收同比大增是因将医药公司、王老吉药业纳入公司合并范围,使得本期营收发生额增加166.14亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.